{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nguyen NHK"],"funding":["NHGRI NIH HHS","NCI NIH HHS"],"pagination":["1769-1783"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10182178"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(9)"],"pubmed_abstract":["Etoposide is used to treat a wide range of malignant cancers, including acute myeloid leukemia (AML) in children. Despite the use of intensive chemotherapeutic regimens containing etoposide, a significant proportion of pediatric patients with AML become resistant to treatment and relapse, leading to poor survival. This poses a pressing clinical challenge to identify mechanisms underlying drug resistance to enable effective pharmacologic targeting. We performed a genome-wide CRISPR/Cas9 synthetic-lethal screening to identify functional modulators of etoposide response in leukemic cell line and integrated results from CRISPR-screen with gene expression and clinical outcomes in pediatric patients with AML treated with etoposide-containing regimen. Our results confirmed the involvement of well"],"journal":["Blood advances"],"pubmed_title":["Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML."],"pmcid":["PMC10182178"],"funding_grant_id":["T32 HG008958","R01 CA132946"],"pubmed_authors":["Seligson N","Elsayed AH","Rubnitz J","Pounds SB","Loguinov A","Rafiee R","Nguyen NHK","de Jesus Sosa AK","Lamba JK","Sobh A","Downing J","Cao X","Tagmount A","Gbadamosi M","Vulpe CD","Cogle CR","Ribeiro R"],"additional_accession":[]},"is_claimable":false,"name":"Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML.","description":"Etoposide is used to treat a wide range of malignant cancers, including acute myeloid leukemia (AML) in children. Despite the use of intensive chemotherapeutic regimens containing etoposide, a significant proportion of pediatric patients with AML become resistant to treatment and relapse, leading to poor survival. This poses a pressing clinical challenge to identify mechanisms underlying drug resistance to enable effective pharmacologic targeting. We performed a genome-wide CRISPR/Cas9 synthetic-lethal screening to identify functional modulators of etoposide response in leukemic cell line and integrated results from CRISPR-screen with gene expression and clinical outcomes in pediatric patients with AML treated with etoposide-containing regimen. Our results confirmed the involvement of well","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2026-07-15T01:42:15.682Z","creation":"2025-04-05T21:07:44.637Z"},"accession":"S-EPMC10182178","cross_references":{"pubmed":["36111891"],"doi":["10.1182/bloodadvances.2022007934"]}}